

August 25, 2023

Coloplast Corporation Troy Thome Senior Regulatory Affairs Specialist 1601 West River Road North Minneapolis, MN 55411

Re: K230165

Trade/Device Name: Luja Coude Regulation Number: 21 CFR§ 876.5130 Regulation Name: Urological Catheter and Accessories Regulatory Class: II Product Code: EZD Dated: July 28, 2023 Received: July 28, 2023

Dear Troy Thome:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

Page 2

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <u>https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems</u>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</u>) and CDRH Learn (<u>https://www.fda.gov/training-and-continuing-education/cdrh-learn</u>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</u>) for more information or contact DICE by email (<u>DICE@fda.hhs.gov</u>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Jessica K. Nguyen -S

Jessica K. Nguyen, Ph.D. Assistant Director DHT3B: Division of Reproductive, Gynecology and Urology Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number *(if known)* K230165

Device Name Luja Coude

#### Indications for Use (Describe)

Luja Coude is indicated for use by patients with urine retention and patients with post void residual volume (PVR) due to neurogenic and non-neurogenic voiding dysfunction. The catheter is inserted into the urethra to reach the bladder allowing urine to drain. The product is for adult male patients only.

Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov* 

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



### **TRADITIONAL 510(K) SUMMARY**

Submitted by:	Coloplast A/S Holtedam1 3050 Humlebaek Denmark
Contact Person:	Troy Thome Sr. Regulatory Affairs Specialist Coloplast 1601 West River Road North Minneapolis MN 55411 Phone: +1 (612)-356-9917 Email: ustbthome@coloplast.com
Date of Summary:	August 24, 2023
Subject Device:	
Trade or Proprietary Name:	Luja Coude
Item/Model Numbers:	20118, 20111, 20112, 20114, 20101, 20102, 20104, 20106
Common Name:	Urological catheter and accessories
Regulation/Classification Name:	Urological catheter and accessories
<b>Regulation Number:</b>	21 CFR 876.5130
<b>Regulatory Class:</b>	ΙΙ
Product Code:	EZD



<b>Review Panel:</b>	Gastroenterology/Urology
Predicate Device:	K190620, SpeediCath Flex Coude Pro The predicate device has not been subject of a design-related recall.
Reference Device:	K180258, SpeediCath Standard The reference device has not been subject of a design-related recall.
Device Description:	Luja Coude is a single-use, sterile catheter for intermittent urinary catheterization. The catheter has a flexible tip which contains several small holes (micro holes) by the tip creating a drainage zone which allows the urine to flow from the bladder through the catheter. The drainage end of the device has an outlet to which a urine bag with a suitable connector can be connected. The catheter also contains a hydrophilic-coating and is sterilized by irradiation.
	The primary packaging provides the sterile barrier and contains a proof of seal for identification of opened products.
	Luja Coude is available in one length (33cm) with a flexible tip and diameters of 8 Fr, 10 Fr, 12 Fr, 14 Fr, and 16 Fr. The reference device supports the inclusion of 8 Fr models.
Indications for Use:	Luja Coude is indicated for use by patients with urine retention and patients with post void residual volume (PVR) due to neurogenic and non-neurogenic voiding dysfunction. The catheter is inserted into the urethra to reach the bladder allowing urine to drain. The product is for adult male patients only.
	The subject and predicate devices have the same intended use.

### **Technological Characteristics Comparison**

The table below summarizes the technological characteristics of Luja Coude as compared to the predicate device.

Parameter	Subject device	Predicate device	Reference device
	Luja Coude	SpeediCath Flex Coudé Pro	SpeediCath Standard (male models only)
510(k) Number	Unassigned	K190620	K180258
Regulation Name	Urological catheter and accessories	Same	Same
Regulation Number	21 CFR 876.5130	Same	Same
Product Code	EZD	GBM	GBM
Classification	II	Same	Same

This file contains proprietary information and should not be disclosed without the consent of Coloplast.



Parameter	Subject device	Predicate device	Reference device
	Luja Coude	SpeediCath Flex Coudé Pro	SpeediCath Standard (male models only)
Prescription Device	Yes	Same	Same
Intended Use	Intermittent catheterization through the urethra.	Same	Same
Condition of Use	Intermittent use and single use	Same	Same
Drainage	Micro holes	Eyelets	Eyelets
Device Categorization per ISO 10993	Surface contacting device in contact with mucosal membrane for a prolonged duration of time (24 h < t< 30 days)	Same	Same
Sterility	SAL 10 <sup>-6</sup>	Same	Same
Sterilization Method	e-beam	Same	Same
Shelf Life	8 months at time of submission (planned 2 years)	2 years	2 years
Available Sizes	Male, FR 8 / CH 8 Male, FR 10 / CH 10 Male, FR 12 / CH 12 Male, FR 14 / CH 14 Male, FR 16 / CH 16	FR 10 / CH 10 FR 12 / CH 12 FR 14 / CH 14 FR 16 / CH 16	Male, FR 8 / CH 8 Male, FR 10 / CH 10 Male, FR 12 / CH 12 Male, FR 14 / CH 14 Male, FR 16 / CH 16 Male, FR 18 / CH 18 Tiemann, FR 10 / CH 10 Tiemann, FR 12 / CH 12 Tiemann, FR 14 / CH 14 Tiemann, FR 16 / CH 16
Catheter Materials	Polyurethane	Same	Similar
Hydrophilic Coating	Polyvinylpyrrolidone (PVP) based	Same	Same
Swelling media (Wetting Agent)	Saline solution with PEG	Same	Same
Tip Configuration	Flexible curved tip (bended)	Same	Straight (Nelaton) tip and Tiemann tip
Protective Sleeve Material	<ul> <li>Copoly (ethylene/octane)</li> <li>Copoly (isobutylene/styrene)</li> </ul>	Same	N/A
Inner Connector	Polyurethane White	Same	N/A no inner connector



Parameter	Subject device	Predicate device	Reference device
	Luja Coude	SpeediCath Flex Coudé Pro	SpeediCath Standard (male models only)
Outer Connector material	Thermoplastic Polypropylene	Same with turquoise color	Thermoplastic polyurethane with masterbatches
Handle material	Thermoplastic Polypropylene	Same with turquoise color	N/A
Primary Packaging Description	Single and double-loop pouch packages, dark grey	Single and double-loop pouch packages, grey	Similar (longer and thicker), green
Packaging Materials	Inner layer: PE-peel Outer layer: Printed PETP	Same	Oriented polyamide, aluminum, low-density polyethylene, ring-shaped opening feature
Effective Catheter Length	Effective length (according to ISO 20696:2018):	Same	Effective length (according to ISO 20696:2018):
	33cm (13 inches)		35cm (13.9 inches)

# Summary of Non-Clinical Performance Testing

Non-clinical test	Bench performance testing and usability testing were conducted to verify the
summary:	proposed subject devices met the pre-determined acceptance criteria per specified
Summary.	requirements. Testing was performed on final, finished, and sterilized devices as
	described in the applicable submission sessions.
<b>Biocompatibility:</b>	ISO 10993-1 :2018, Biological evaluation of medical devices – Part 1: Evaluation of
y.	testing within a risk management process
	ISO 10993-5 :2009, Biological evaluation of medical devices – Part 5: Test for in
	vitro cytotoxicity
	ISO 10993-10 :2021, Biological evaluation of medical devices, Part 10: Test for
	irritation and skin sensitization
	ISO 10993-11 :2017, Biological evaluation of medical devices, Part 11: Tests for
	systemic toxicity
	ISO 10993-18 :2020, Biological evaluation of medical devices, Part 18: Chemical
	characterization of medical device materials within a risk management process
	ISO 10993-23 :2021, Biological evaluation of medical devices, Part 23: Tests for
	irritation
The following biologic	al endpoints were addressed: cytotoxicity, irritation or intracutaneous reactivity,
sensitization, material	mediated pyrogenicity, acute systemic toxicity, and subacute toxicity.
Catheter	ISO 20696: 2018, Sterile urethral catheters for single use
performance:	ASTM F623-19, Standard performance specification for Foley Catheter
	ASTM D1894: 2014, Standard test method for static and kinetic coefficients of
	friction of plastic film and sheeting
	Coloplast Test Method TM 6058 Friction after 5 minutes
	Coloplast Test Method TM 6059 opening torque
	Coloplast Test Method TM 6100 sleeve collapse force
	Coloplast Test Method TM6129: Kink and Coude measurement
	EN/IEC 62366-1:2015/A1:2020 Medical devices — Part 1: Application of usability
	engineering to medical devices

This file contains proprietary information and should not be disclosed without the consent of Coloplast.



Bench performance testing and usability testing were conducted to verify the proposed subject devices met the pre-determined acceptance criteria per specified requirements. Testing was performed on final, finished, and sterilized devices as described in the applicable submission sessions.

sterilized devices as des	cribed in the applicable submission sessions.
Packaging:	ISO 11607-1 :2019, Packaging for terminally sterilized medical devices – Part 1:
	Requirements for materials, sterile barrier systems and packaging systems
	ASTM F2096 Standard Test Method for Detecting Gross Leaks in Packaging by
	Internal Pressurization (Bubble Test)
	EN 868-5 Packaging for terminally sterilized medical devices Sealable pouches and
	reels of porous materials and plastic film construction. Requirements and test
	methods
	ASTM F88/FM88 Standard Test Method for Seal Strength of Flexible Barrier
	Materials.
	ASTM D4169-22 Standard Practice for Performance Testing of Shipping Containers
	and Systems
Packaging integrity testing was conducted to verify the maintenance of the sterile barrier through shelf life. Transportation testing was conducted to verify that there is no impact to the device safety or efficacy of the	
catheter performance du	te to the hazards associated with the transportation environment.
Aging:	ASTM F1980-21, Standard guide for accelerated aging of sterile barrier systems and medical devices
The stability study investigated whether there were unexpected (significant) changes in product properties over the shelf life of the device. The properties meet the acceptance criteria after the aging cycle, the device is	

the shelf-life of the device. The properties meet the acceptance criteria after the aging cycle, the device is therefore deemed to be stable for the defined shelf life.

### Conclusion

The performance testing demonstrates the subject device is as safe and effective as the predicate device.